<DOC>
	<DOCNO>NCT02587247</DOCNO>
	<brief_summary>Evaluation sensitivity immuno-PET PET / CT pretargeted bispecific anti-CEA x anti-HSG TF2 antibody IMP-288 peptide label Gallium-68 image potential candidate patient surgery local resection one metastases diagnosis relapse CCR express CEA .</brief_summary>
	<brief_title>ImmunoTEP With 68-Ga Metastatic Colo Rectal Cancer</brief_title>
	<detailed_description>Injection bispecific anti-CEA x anti-HSG antibody TF2 ( 120 nmoles ) 30 hour later IMP-288 peptide label gallium-68 ( 3 6 nmoles/150 MBq ) . A TEP image acquisition plannified 60 min 68-Ga injection .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Existence one metastases colorectal cancer ( CRC ) express CEA , potentially accessible surgical thermo resection moment diagnosis relapse . OR Isolated progressive elevation plasma CEA monitoring CRC high metastatic risk More 18 year Negative pregnancy test woman childbearing age . Women childbearing age take effective continuous contraception 3 month . At least 4 week last treatment recovery potential toxicity Karnofsky 70 ECOG 01 Life expectancy least 6 month CEA positive immunohistochemistry plasma CEA supperior equal normal level Creatinin le equal 200 micromol/L Signed informed consent geographical proximity Pregnancy breastfeed Serious illness comorbidity assess risk History cancer within 5 year , exception skin carcinoma melanoma insitu carcinoma cervix Antiantibody presence patient already receive antibody Hypersensitivity antibodies proteins Intellectual inability sign inform consent Insulindependent diabetic patient noninsulin dependent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>